Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP13 | P45452 | 2/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27805611 | 1.00 | SLC7A5 (0.40) | SLC7A5LTA4HSIRT2HSD17B10CYP3A4 | |
| SCHEMBL7018374 | 0.85 | ACACB (0.43) | SLC7A5LTA4HLMNAPOLBMAPT | |
| SCHEMBL13550948 | 0.85 | SIRT2 (0.38) | SIRT2MMP2MMP9MMP8MMP13 | |
| SCHEMBL4200153 | 0.85 | ALDH1A1 (0.45) | SLC7A5LTA4HSIRT2HSD17B10MMP2 | |
| SCHEMBL10562986 | 0.81 | CTSS (0.47) | SLC7A5LTA4HCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7340685 | 0.81 | CTSS (0.47) | SLC7A5LTA4HCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17468539 | 0.80 | TPH1 (0.40) | SLC7A5LTA4HCTSSCTSK | |
| SCHEMBL28526417 | 0.80 | TPH1 (0.40) | SLC7A5LTA4HCTSSCTSK | |
| SCHEMBL1429937 | 0.80 | HDAC1 (0.47) | SLC7A5LTA4HMAPTTDP1NPR3 | |
| SCHEMBL13908319 | 0.80 | MAPT (0.47) | SIRT2MMP9POLBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201581-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902181-B2 | Compounds 010 | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306042-A1 | Novel Compounds 010 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009074829-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2049490-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL]-L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | Astra Zeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008093065-A1 | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-08-07 | — | — | WO | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | SLC7A5 279/4885LTA4H 951/4885SIRT2 4131/4885 |
| US-20090306042-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | SLC7A5 3657/4885LTA4H 1099/4885SIRT2 2853/4885 |
| US-20090062267-A1 | L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS | ITGA2B, ITGB1, ITGAL | SLC7A5 197/4885LTA4H 392/4885SIRT2 3474/4885 |
| US-20110201581-A1 | Novel Compounds 010 | MRGPRX2, F12, TBXA2R | SLC7A5 3657/4885LTA4H 1099/4885SIRT2 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.